Company News

Share this article:

Allergan filed a declaratory relief action in a US District Court against the FDA, that, if successful, would allow the company to market Botox off-label. Allergan is arguing that some of the off-label uses for Botox are medically accepted and commonly prescribed, but are currently unapproved by FDA. Allergan said in a statement that the law against communicating truthful information to physicians about off-label uses of its products violates the company's First Amendment rights, and is inconsistent with the Federal Food, Drug & Cosmetic Act. The lawsuit does not include a specific product, but takes issue with the law in general.

Health information transfer and marketing tech firm iMedicor signed an agreement with Access Pharmaceuticals to launch and market MuGard, Access Pharmaceuticals' oral wound rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy. MuGard has an estimated worldwide market over $5 billion, according to a company statement. iMedicor will deliver targeted online marketing messages to 216,000 specialty medical practices across the US through its iMedicor portal, as part of the agreement.    


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.